|
14 Apr 2025 |
Jyothy Labs
|
Consensus Share Price Target
|
366.80 |
472.54 |
- |
28.83 |
buy
|
|
|
|
|
11 Mar 2025
|
Jyothy Labs
|
Geojit BNP Paribas
|
366.80
|
395.00
|
333.90
(9.85%)
|
7.69 |
Buy
|
|
|
|
|
01 Feb 2025
|
Jyothy Labs
|
Axis Direct
|
366.80
|
450.00
|
415.70
(-11.76%)
|
22.68 |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
31 Jan 2025
|
Jyothy Labs
|
Sharekhan
|
366.80
|
490.00
|
398.40
(-7.93%)
|
33.59 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q3FY25 performance was muted with revenue growing by just 4%, while a ~110 bps y-o-y decline in OPM led to 4% y-o-y decline in PAT.
|
|
04 Dec 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
366.80
|
496.00
|
411.15
(-10.79%)
|
35.22 |
Buy
|
|
|
|
|
13 Nov 2024
|
Jyothy Labs
|
Axis Direct
|
366.80
|
500.00
|
436.10
(-15.89%)
|
36.31 |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
12 Nov 2024
|
Jyothy Labs
|
Sharekhan
|
366.80
|
575.00
|
441.35
(-16.89%)
|
56.76 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q2FY2025 performance was muted with revenue and PAT remaining flat y-o-y. OPM at 18.9% rose by 38 bps y-o-y.
|
|
12 Nov 2024
|
Jyothy Labs
|
Motilal Oswal
|
366.80
|
500.00
|
441.35
(-16.89%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported flat sales YoY (miss) in 2QFY25. It posted a five-year CAGR of 10%. Volume growth was at 3%, on account of a high base.
|
|
13 Aug 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
366.80
|
645.00
|
548.10
(-33.08%)
|
75.85 |
Accumulate
|
|
|
|
|
26 Jul 2024
|
Jyothy Labs
|
Axis Direct
|
366.80
|
600.00
|
548.45
(-33.12%)
|
63.58 |
Buy
|
|
|
We maintain our long-term BUY rating on the stock.
|
|
25 Jul 2024
|
Jyothy Labs
|
Motilal Oswal
|
366.80
|
565.00
|
547.70
(-33.03%)
|
Target met |
Neutral
|
|
|
Jyothy Laboratories (JYL) reported a revenue growth of 8% YoY (in line) in 1QFY25. It delivered a volume growth of 11% and continued to focus on volume-led growth to gain market share across categories.
|
|
25 Jul 2024
|
Jyothy Labs
|
Sharekhan
|
366.80
|
655.00
|
547.70
(-33.03%)
|
78.57 |
Buy
|
|
|
Jyothy Labs Limited’s (JLL’s) Q1FY2025 operating performance was in line with our expectation with revenues growing by 8% (versus expectation of 8.5%) while OPM stood at 18% (versus expectation of 17.9%).
|
|
25 Jul 2024
|
Jyothy Labs
|
ICICI Securities Limited
|
366.80
|
640.00
|
547.70
(-33.03%)
|
74.48 |
Buy
|
|
|
JYL’s Q1FY25 volume growth of 11% YoY is a material outperformance vs peers on a higher base as it continues to focus on direct distribution expansion, innovation, new SKUs coupled with continued investment behind the brands.
|
|
29 May 2024
|
Jyothy Labs
|
Geojit BNP Paribas
|
366.80
|
478.00
|
413.25
(-11.24%)
|
Target met |
Accumulate
|
|
|
|
|
16 May 2024
|
Jyothy Labs
|
Axis Direct
|
366.80
|
500.00
|
446.40
(-17.83%)
|
Target met |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
09 Mar 2024
|
Jyothy Labs
|
Axis Direct
|
366.80
|
475.00
|
429.50
(-14.60%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 475/share, implying an upside of 10% from the CMP.
|
|
23 Feb 2024
|
Jyothy Labs
|
Sharekhan
|
366.80
|
590.00
|
467.05
(-21.46%)
|
Target met |
Buy
|
|
|
|
|
23 Feb 2024
|
Jyothy Labs
|
Sharekhan
|
366.80
|
590.00
|
475.65
(-22.88%)
|
Target met |
Buy
|
|
|
|
|
01 Feb 2024
|
Jyothy Labs
|
Axis Direct
|
366.80
|
565.00
|
508.20
(-27.82%)
|
Target met |
Buy
|
|
|
With a 10% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
01 Feb 2024
|
Jyothy Labs
|
Motilal Oswal
|
366.80
|
500.00
|
508.20
(-27.82%)
|
Target met |
Neutral
|
|
|
|
|
16 Nov 2023
|
Jyothy Labs
|
Geojit BNP Paribas
|
366.80
|
405.00
|
439.20
(-16.48%)
|
Target met |
Sell
|
|
|
|